Cellular Prion Protein Sensitizes Neurons to Apoptotic Stimuli through Mdm2-regulated and p53-dependent Caspase 3-like Activation*

Erwan PaitelDagger , Robin Fahraeus§, and Frédéric CheclerDagger

From the Dagger  Institut de Pharmacologie Moléculaire et Cellulaire of CNRS, UMR6097, Valbonne, France and the § Division of Molecular Physiology, Dundee University, Dundee, United Kingdom

Received for publication, November 13, 2002, and in revised form, January 10, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We examined the influence of cellular prion protein (PrPc) in the control of cell death in stably transfected TSM1 cells. PrPc expression enhanced staurosporine-stimulated neuronal toxicity and DNA fragmentation, caspase 3-like activity and immunoreactivity, and p53 immunoreactivity and transcriptional activities. Caspase activation was reduced by the chemical inhibitor of p53, pifithrin-alpha , as well as by PrPc- or p53-antisense approaches but remained insensitive to the Fyn kinase inhibitor PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine). We establish that PrPc controls p53 at a post-transcriptional level and is reversed by Mdm2 transfection and p38 MAPK inhibitor. We propose that endogenous cellular prion protein sensitizes neurons to apoptotic stimuli through a p53-dependent caspase 3-mediated activation controlled by Mdm2 and p38 MAPK.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Prion-associated pathologies are transmissible diseases that all have fatal issues (1, 2). The elucidation of their etiology has revealed a fully original transmission mechanism. It is now generally admitted that the pathological infectious mechanism is due to a protein present ubiquitously in the brain (referred to as PrPc)1 that becomes deleterious after its biophysical conversion into a protease-resistant protein referred to as PrPres or PrP-scrapie (3). This "bio-transformation" and subsequent pathologies absolutely require the presence of PrPc because the absence of endogenous PrPc totally precludes the PrPsc-mediated infectivity and neurotoxicity (4, 5).

Most of the works on prions have focused on these intriguing disease-related features, particularly their conformation properties in vitro (6-8) and the species barrier allowing or limiting the propagation of the various prion strains (for reviews see Refs. 1 and 2). The invalidation of the PrP gene (Prnp) led to the conclusion that the Prnp-/- mice exhibit normal development and unaltered behavioral phenotype (9, 10).

Several clues of a possible participation of PrPc in programmed cell death came from the identification of a significant but restricted sequence homology of PrPc octapeptide repeats with the anti-apoptotic oncogene Bcl-2 protein and its ability to bind to Bcl-2 in double hybrid approach (11-12). A recent study (13) also indicated that prion protein could rescue human neurons from Bax-induced apoptosis. Alternatively, the possibility that a restricted sequence corresponding to the 106-126 part of the molecule could elicit a cellular toxic response has also been extensively documented (14-16).

It is noteworthy that the 106-126 domain of the prion protein has no genuine physiological or pathological existence as it has never been described as a catabolite of PrPc that would have been proteolytically generated upon normal or pathological conditions. Therefore, the "toxic" potential of the 106-126 peptide could either be not relevant to any normal or altered situation or, alternatively, could reflect a phenotype that would be also triggered by the whole parent prion protein. The latter hypothesis would be in contradiction with the above studies, suggesting an anti-apoptotic PrPc-related phenotype, but would be in line with the work of Westaway et al. (17), showing that transgenic mice over-expressing "normal" wild type PrPc exhibit degeneration in central and peripheral nervous system as well as in skeletal muscle. Interestingly, the 106-126 domain appears to be targeted by a set of proteolytic activities called disintegrins, ADAM10 and ADAM17, that cleave PrPc at the 110/111 peptide bond and thereby "inactivate" the putative toxic core of the PrPc protein (18). To establish a pro- or anti-apoptotic PrPc-mediated phenotype, we have examined the possible toxicity of PrPc and its putative involvement in the control of cell death. We show that in TSM1 cells, over-expressed and endogenous PrPc all trigger p53-dependent caspase 3 activation leading to a pro-apoptotic phenotype.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transfected TSM1 Cells and p53-inactive Cells-- Murine TSM1 neuronal cells (19) stably expressing mouse 3F4-tagged MoPrPc (3F4MoPrPc) were obtained and cultured as previously described (18). PrPc- or p53-antisense cDNAs (referred to as ASPrP or ASp53, respectively) were obtained after transfection of 1 µg of antisense pcDNA3 vector bearing 3F4MoPrPc or p53 with DAC30 (Eurogentec). Doubly transfected 3F4MoPrPc/ASp53 TSM1 cells were obtained after transfection of 3F4MoPrPc-expressing cells with ASp53 cDNA. p53-inactive cells were obtained from ATCC (NCI-H1299 clone) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.

Western Blot Analyses-- Cells were scraped and homogenized in lysis buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 5 mM EDTA containing 0.5% Triton X-100 and 0.5% sodium deoxycholate). Equal amounts of protein (50 µg) determined by the Bradford method (20) were separated on 12% SDS-PAGE gels and analyzed for their p53, active caspase 3, Mdm2, phospho-p38, and PrPc immunoreactivities by Western blot and hybridization with anti-p53 (mouse monoclonal, Pab24, Santa Cruz Biotechnology), anti-active caspase 3 (rabbit polyclonal R&D System), mouse monoclonal anti-Mdm2, anti-phospho-p38 (Promega, Charbonnières-les Bains, France) and anti-PrPc (SAF32, Ref. 21), respectively. The secreted N-terminal fragment (N1) of PrPc was recovered after incubation for 8 h at 37 °C/5% CO2 in serum-free medium. Medium was then incubated overnight with 2 µg/ml SAF32 monoclonal and protein A-Sepharose (Zymed Laboratory Inc.) and analyzed using sheep anti-mouse peroxydase-conjugated secondary antibody (dilution 1:10,000, Amersham Biosciences) as described (18).

Flow Cytometry Analysis-- Cells were grown in 6-well plates and incubated for 15 h at 37 °C in the presence or absence of staurosporine (0.5 µM). Cells were rinsed with phosphate-buffered saline, resuspended with 750 µl of buffer (20 mM Tris, 0.1% tri-natrium citrate, 0.05% Triton X-100) containing 50 µg/ml propidium iodide (PI) and incubated overnight at 4 °C. The PI fluorescence of individual nuclei was measured using a FACSCalibur flow cytometer (CellQuest software; BD Biosciences). Nuclei were characterized for their side angle scatter and forward-angle scatter parameters. Red fluorescence due to PI staining of DNA was then counted on a logarithmic scale. All measurements were performed under identical conditions. This technique allows discrimination of populations of fragmented nuclei from debris and non-viable cells and also from intact diploid nuclei those show higher fluorescence staining. The number of apoptotic nuclei is expressed as a percentage of the hundred thousand events gated.

XTT Assay of Cell Viability-- Cells were grown in a 5% CO2 atmosphere in 96-well plates in a final volume of a 100 µl per well and incubated for 24 h at 37 °C in the presence or absence of 2 µM of staurosporine. Briefly, XTT is metabolized by mitochondrial dehydrogenase to a water soluble formazan salt only by metabolically active viable cells. XTT metabolizing activity was determined as previously described (22).

Caspase 3-like Activity Assay-- Cells were cultured in 6-well plates for 15 h at 37 °C in the absence or presence of etoposide, ceramide C2, or staurosporine (0.5 µM) or 15 µM of the Fyn kinase inhibitor PP2. In some cases, cells were pre-incubated for 24 h with Ac-DEVD-al (100 µM) or for 2 h with the p38 MAPK inhibitor SB203580 (1 µM, Calbiochem). Cells were then rinsed, gently scraped, pelleted by centrifugation, then resuspended in 40 µl of lysis buffer and analyzed as previously detailed (22).

p53 Transcriptional Activity-- The PG13-luciferase p53 gene reporter construct (provided by Dr. B. Vogelstein) has been previously described (23). One µg of PG13-luciferase was co-transfected with 1 µg of a beta -galactosidase transfection vector (to normalize transfections efficiencies) in TSM1 neurons and in PrP+/+ and PrP-/- primary cultured neurons. Forty-eight hours after transfection, luciferase and beta -galactosidase activities were measured according to previously described procedures (23).

Statistical Analysis-- Statistical analyses were performed with Prism software (Graphpad Software, San Diego, CA) using Newman-Keuls multiple comparison test for one-way analysis of variance and the unpaired Student's t test for pair-wise comparisons.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PrPc Over-expression Increases Basal and Staurosporine-induced Toxicity and DNA Fragmentation in TSM1 Neurons-- We have obtained stable TSM1 transfectants over-expressing 3F4MoPrPc (Fig. 1A, upper panel). As expected, these cells secrete higher amounts of a 11-12-kDa fragment (Fig. 1A, lower panel), the immunological characterization of which previously led to its identification as the N-terminal product (called N1) derived from proteolysis of PrPc at the 110/111-112 peptide bond (18). The over-expression of PrPc in TSM1 neurons increases both basal and staurosporine-induced toxicity (Fig. 1B) and DNA fragmentation (Fig. 1C) as measured by XTT and PI incorporation, respectively. This phenotype has been observed for all clones examined (not shown).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 1.   Caspase activation, enhanced toxicity, and DNA fragmentation in PrPc-expressing TSM1 neurons. A, over-expression of PrPc and its secreted product N1 in 3F4MoPrPc-TSM1 neurons was measured by Western blot with SAF32 as described under "Experimental Procedures" (#1-3 represent three independent clones). B, TSM1 viability in basal and staurosporine-treated conditions. Mock-(black bars) or PrPc-expressing (gray bars) cell lines were treated without (-) or with (+) staurosporine (Sts) then assayed for their XTT metabolizing activity as described under "Experimental Procedures." Activities are expressed as the percentage of the control (mock cells in the absence of staurosporine). Bars are the means ± S.E. of 9 independent experiments (triplicate determinations). C, basal and staurosporine-stimulated PI incorporation measured in the indicated cell lines by fluorescence-activated cell sorter analysis (similar data were obtained in 3 independent experiments). The number of apoptotic nuclei is estimated as described under "Experimental Procedures." D, caspase 3 activity and immunoreactivity (for details see "Experimental Procedures") in basal (-) and Sts (+) conditions in mock-transfected (black bars) or PrPc-expressing TSM1 neurons (gray bars). Bars represent the Ac-DEVD-al-sensitive caspase 3-like activity and are the means ± S.E. of 7 determinations (duplicate determinations; ns, non-statistically significant). E, effect of the indicated apoptotic effectors on caspase 3 activity in mock-transfected (black bars) or PrPc-expressing TSM1 neurons (gray bars) measured as in D. Bars represent the means ± S.E. of 4-7 (duplicate determinations). F, caspase 3 activity (for details see "Experimental Procedures") in basal (-) and Sts (+) conditions in mock-transfected (black bars) or PrPc-expressing TSM1 neurons (grey bars) after PP2 pretreatment (for details see "Experimental Procedures").

Staurosporine-induced Caspase 3 Activation is Increased by PrPc Over-expression in TSM1 Neurons-- Over-expression of PrPc increases staurosporine-stimulated but not basal Ac-DEVD-al-sensitive Ac-DEVD-7AMC-hydrolyzing caspase 3-like activity in TSM1 neurons (Fig. 1D). This was accompanied by an augmentation of staurosporine-induced active caspase 3-like immunoreactivity (Fig. 1D). It should be emphasized that PrPc expression potentiated the increase of caspase 3 activity triggered by several other apoptotic stimuli such as ceramide C2 and etoposide in TSM1 (Fig. 1E). PP2, a selective inhibitor of kinases belonging to the Src family, such as Lck and Fyn, (24) did not affect the extent of PrPc-induced staurosporine-stimulated caspase 3 activation in TSM1 neurons (Fig. 1F).

PrPc Antisense Approach Lowers Staurosporine-induced Caspase 3 Activation and DNA Fragmentation in TSM1 Neurons-- To examine the endogenous contribution of PrPc to TSM1 susceptibility to staurosporine, we set up stable antisense-PrPc (ASPrPc) TSM1 transfectants. This antisense approach led to a drastic reduction of endogenous PrPc expression and to a barely detectable N1 secretion (Fig. 2A). Interestingly, the staurosporine-stimulated, but not the basal caspase 3 activity observed in mock-transfected TSM1 neurons, was drastically reduced in ASPrPc-TSM1 cells (Fig. 2B). Concomitantly, PrPc-antisense abolished the staurosporine-induced augmentation of active caspase 3-like immuno-reactivity (Fig. 2B). In line with these observations, the staurosporine-induced DNA fragmentation was reduced by about 50% in ASPrPc-expressing TSM1 neurons (Fig. 2C), a percentage that matched well the extent of the reduction of caspase 3 activity (see Fig. 2B).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 2.   PrP-antisense lowers TSM1 responsiveness to staurosporine. Antisense-PrPc-expressing TSM1 cells (ASPrP) were obtained and cultured as described under "Experimental Procedures." A, ASPrP cells express less endogenous PrPc- and N1-like immuno-reactivities (3 independent clones are shown). B, caspase 3 activity and immuno-reactivity (Casp.3; for details see "Experimental Procedures") in basal (-) and Sts (+) conditions in mock-transfected (black bars) or ASPrP-expressing TSM1 neurons (empty bars). Bars represent the Ac-DEVD-al-sensitive caspase 3-like activity and are the means ± S.E. of 7 experiments (duplicate determinations; ns, non-significant). C, basal and staurosporine-stimulated PI incorporation measured in the indicated cell lines by fluorescence-activated cell sorter analysis. The procedure and estimation of the number of apoptotic nuclei are described under "Experimental Procedures."

PrPc-induced Caspase 3 Activation is p53-dependent in TSM1 Neurons-- We examined the putative contribution of the tumor suppressor oncogene p53 to the PrPc-induced caspase 3 activation and toxicity by antisense and pharmacological approaches. We set up TSM1 stable transfectants expressing p53 antisense cDNA either alone (ASp53) or in combination with 3F4MoPrPc (3F4MoPrPc/ASp53)(see Fig. 4B). Our data show that all 3F4MoPrPc-related phenotypes can be prevented by antisense down-regulation of p53. Thus, Fig. 3A clearly shows that ASp53 drastically protects TSM1 cells from both basal and staurosporine-stimulated PrPc-mediated toxicity measured by the XTT assay (compare 3F4MoPrPc with 3F4MoPrPc/ASp53). Furthermore, ASp53 fully prevents the 3F4MoPrPc-induced DNA fragmentation (Fig. 3D, compare 3F4MoPrPc-sts with 3F4MoPrPc/ASp53-sts). Finally, ASp53 totally reverses the staurosporine-induced caspase activation triggered by 3F4MoPrPc (Fig. 3B, compare 3F4MoPrPc and 3F4MoPrPc/ASp53 transfectants).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   PrPc-induced caspase 3 is p53-dependent. A, mock-, 3F4MoPrPc, or 3F4MoPrPc-TSM1 cells stably transfected with p53 antisense cDNA (3F4MoPrP/ASp53), respectively, were checked for their cell viability in the absence (-) or presence (+) of staurosporine (Sts) as described in the legend to Fig. 1. B-D, TSM1 cells stably transfected with p53 antisense cDNA (ASp53 and 3F4MoPrP/ASp53, respectively) were measured for their caspase activity (B and C) and DNA fragmentation (D) in the absence (-) or presence (+) of staurosporine (B and D) or pifithrin-alpha (Pft, 10 µM, B). Bars represent the means ± S.E. of 3-6 independent determinations (carried out in duplicates).

We took advantage of the recent design of a specific p53 inhibitor, pifithrin-alpha (25), to further confirm the role of endogenous p53 in PrPc-mediated caspase activation. This pharmacological approach allowed us to show that pifithrin-alpha abolishes the 3F4MoPrPc-mediated staurosporine-stimulated increase of caspase 3 activity (Fig. 3C, compare 3F4MoPrPc and Mock -/+pft). Interestingly, pifithrin-alpha appeared inactive in ASp53-TSM1 cells (Fig. 3C, compare ASp53 -/+pft), indicating that the antisense and pharmacological approaches indeed inhibited the same expected molecular target, i.e. p53. This conclusion was reinforced by the fact that pifithrin-alpha did not significantly modify caspase 3 activity displayed by doubly transfected 3F4MoPrPc/ASp53-TSM1 neurons that remain at the level of pifithrin-alpha -treated mock- and 3F4MoPrP-transfected cells (Fig. 3C).

PrPc-expression Increases p53-like Immunoreactivity and Activity-- Because PrPc-proapoptoptic phenotype appeared p53-dependent, we examined whether PrPc could also affect p53 expression and transcriptional activity. First, our data show that TSM1 over-expressing 3F4MoPrPc displays higher endogenous p53-like immunoreactivity than mock-transfected cells (Fig. 4A). This was also observed in transfected HEK293 cells (Fig. 4E). Conversely, ASPrPc-TSM1 cells exhibit lower p53-like immunoreactivity (Fig. 4A). To correlate the modulation of p53 immunoreactivity with its biological activity, we examined the p53 transcriptional activity by means of the PG13-luciferase construct classically used as the p53 gene reporter (23). Interestingly, p53 transcriptional activity was drastically enhanced in 3F4MoPrPc-TSM1 cells (Fig. 4C) and lowered in ASPrPc-expressing neurons (Fig. 4C). As expected, ASp53-expressing cells exhibit lower p53 immunoreactivity (Fig. 4B, compare ASp53 and Mock) and totally prevents the p53 increase observed with singly transfected 3F4MoPrPc cells (Fig. 4B, compare 3F4MoPrP and 3F4MoPrP/ASp53 with ASp53).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   PrPc modulates p53-like immuno-reactivity and transcriptional activity. p53-like immuno-reactivity (A, B) and transcriptional activity (C) were monitored as described under "Experimental Procedures" in the indicated transfected TSM1 (A-C). Bars are the means ± S.E. of 4-6 independent experiments (duplicate and triplicate determinations).

PrPc Controls p53 at a Post-transcriptional Level-- We took advantage of a cell system in which p53 is functionally deficient (26) to examine the ability of PrPc to increase p53 expression in co-transfection experiments. Any PrPc-dependent increase in p53 could not be explained by a transcriptional activation as the p53 cDNA is driven by a cytomegalovirus promoter and therefore would imply post-transcriptional PrPc-dependent p53 modulation. As expected, mock-transfected cells do not display any p53 transcriptional activity (Fig. 5A). PrPc cDNA transfection does not modify this null phenotype. However, we establish that transient co-transfection of PrPc and p53 cDNAs drastically potentiates the p53 transcriptional activity associated with p53 cDNA transfection alone (compare p53 and 3F4/p53 in Fig. 5A). These data led us to search for post-transcriptional modifications triggered by PrPc that would have altered p53 transcriptional activity. Mdm2 was recently shown to decrease p53 metabolic stability thereby lowering its activity (27). We demonstrate here that Mdm2 fully reverses the PrPc-induced increase of p53 transcriptional activity (Fig. 5E).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Post-transcriptional regulation of p53 by PrPc. A, p53 transcriptional activity was monitored by means of the PG13-luciferase reporter gene (see "Experimental Procedures") in p53-deficient fibroblasts following transient transfections with 3F4MoPrP (3F4) or wild type p53 (P53) cDNA alone or combined (P53/3F4). Bars are the means of 6 ± S.E. In E, Mdm2 cDNA alone (Mdm2) or in combination with p53 (Mdm2/P53) or 3F4 and p53 (3F4/Mdm2/P53) were analyzed for p53 transcriptional activity as in A. Bars are the means of 3 ± S.E. B and C, phosphorylated-p38 MAPK immuno-reactivity was examined in mock and 3F4MoPrPc stably transfected TSM1 neurons (B) and in p53-deficient fibroblasts following 3F4MoPrP (PrP) and/or wild type p53 (P53) transient transfections (C). D, mock or 3F4MoPrPc cells were treated without (-) or with (+) staurosporine (Sts) in absence (-) or presence of SB203580 (SB) then analyzed for caspase 3 activity as described under "Experimental Procedures." Bars are the means ± S.E. of 4 independent experiments.

As p38 MAPK was reported to up-regulate p53 activity via upstream decrease of Mdm2 expression (28), we examined the effect of a selective p38 MAPK inhibitor (29) and the endogenous levels of the active phosphorylated counterpart of p38 MAPK. SB203580 significantly reduced but did not abolish the staurosporine-induced caspase activation in mock- and 3F4MoPrPc-expressing neurons (Fig. 5D). Accordingly, over-expression of PrPc increases phospho-p38 MAPK immunoreactivity in both TSM1 neurons (Fig. 5B) and p53-inactive fibroblasts (Fig. 5C). Altogether, our data suggest that PrPc increases p53 activity by p38 MAPK activation and concomitant reduction of Mdm2.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Although a series of studies (1-9) attempted to delineate the prions-related pathogenic mechanisms, very few data concern the putative physiological function of PrPc. This lack of attention perhaps came in part from the fact that the absence of the protein does not seem absolutely crucial because mice in which the prnp gene had been invalidated are safe and healthy, with apparently poorly detectable alterations in their development and behavior (9). However, Kuwahara et al. (30) reported that hippocampal neurons prepared from Prnp-/- mice undergo exacerbated cell death triggered by serum deprivation, thereby suggesting that PrPc could display an anti-apoptotic tonus. More recently, an interesting study documented the fact that PrPc protected human neurons from Bax-induced cell death (13). These data are apparently in opposition with a previous work demonstrating that transgenic mice over-expressing wild type PrPc could exhibit severe neurodegeneration (17). On the other hand, a recent article indicated that the post-natal deletion of the PrPc alters CA1 hippocampal neuron excitability but does not induce neurodegeneration (10) as would have been expected if the protein displayed an important anti-apoptotic function at adulthood. Furthermore, an infected hypothalamic neuronal cell line exhibits increased apoptosis (31). Whether this results from a dysfunction in the normal control of cell death by PrPc remains a possibility.

The 106-126 domain of PrPc was shown to be toxic (14, 15) and appears to activate several pro-apoptotic markers (16, 32). This fragment is never proteolytically released as such from PrPc. In this context, either the bulk of studies examining the effect of 106-126 just describe not relevant and artifactual data, or, more likely, the studies carried out with this fragment can be seen as a revelator of a PrPc function that would be pro-apoptotic. Our study clearly establishes by means of neuronal cell systems, stable transfections, antisense, and pharmacological approaches that PrPc drastically exacerbates cell responsiveness to pro-apoptotic stimuli. Thus, over-expression or specific induction of PrPc enhances staurosporine-induced cell toxicity, DNA fragmentation, and increases both caspase 3-like activity and immuno-reactivity that are all reversed by PrPc antisense approach. The fact that PrPc-mediated caspase activation also occurs in HEK293 cells (33) importantly indicates that the pro-apoptotic PrPc-related phenotype is not cell-specific.

A recent study (34) suggested that PrPc could behave as a signaling molecule, transducing the signal after its coupling to the Src kinase Fyn. In our experiments, the selective Src inhibitor PP2 does not affect the PrPc-induced caspase activation, indicating that Fyn kinase phosphorylating activity was clearly not essential for PrPc-induced apoptosis in our experimental conditions. It should be noted that distinct cell types were used in the two studies, and more particularly the Fyn-dependent PrPc-mediated signaling appeared drastically dependent on the differentiation state of the 1C11 cells used in Mouillet-Richard et al. (35). Clearly the lack of Fyn dependence observed for PrPc-mediated phenotype in TSM1 cells indicates that Fyn requirement is likely restricted to few specialized PrPc phenotypes much more than for more general PrP function in cell death control.

We demonstrate that the PrPc-induced caspase 3 activation is mediated by p53. Indeed, PrPc expression increases p53 immuno-reactivity and transcriptional activity, whereas the PrPc antisense approach led to the opposite phenotype. Furthermore, p53 antisense blocked the PrPc-induced toxicity, DNA fragmentation, and caspase 3 activation. The opposite phenotype triggered by down-regulation of endogenous PrPc importantly indicates that the pro-apoptotic phenotype observed in PrPc-transfected cells was not artifactually related to the procedure involving over-expression of the protein. This is in agreement with our other data showing that Rov9 cells display a pro-apoptotic phenotype only after selective PrPc induction (33).

PrPc controls p53 expression and activity at a post-transcriptional level. Thus we were able to demonstrate that in a cell line deficient in active p53, PrPc drastically increases p53 activity after co-transfection of p53 and PrPc cDNAs. As p53 and PrPc cDNA are driven by a constitutively active cytomegalovirus promoter, p53 enhanced activity cannot be derived from increased transcription of p53, the genuine promoter of which leads to an inactive protein in our cell system. Interestingly, Mdm2 fully prevents the PrPc-induced p53 increase observed in the above cell system. Mdm2 was recently shown to control p53 expression at post-transcriptional levels (27) and particularly modulates p53 ubiquitination and degradation. Therefore, one could conclude that PrPc increases p53 expression and transcriptional activity via a decrease of the p53 down-regulator Mdm2. To support this hypothesis we examined the putative contribution of the p38 mitogen-activated protein kinase that was recently shown to down-regulate Mdm2 and concomitantly increase p53 expression in neurons in a model of hypoxia. Indeed, we clearly showed that phospho-38 MAPK immuno-reactivity, the activated form of this kinase, was higher in PrPc-expressing TSM1 cells, in PrP+/+ than in PrP-/- neurons, and could be increased by PrPc in fibroblasts (see Fig. 5). Furthermore, p38 inhibitor could partly block the PrPc-associated caspase 3 activation in transfected TSM1 neurons. Altogether, our data show that PrPc exerts a pro-apoptotic phenotype through the modulation of caspase 3 activity via a p53-dependent pathway that is positively and negatively controlled by p38 MAPK and Mdm2, respectively.

It is interesting to note that a recent study indicated that misfolded PrPc could be neurotoxic and could induce neurodegenerescence when accumulating in the cytosol, even at small amounts (35). Whether such a small amount of PrPc could account for the phenotype observed in our over-expression system is difficult to examine. However, the fact that our antisense approach led to an anti-apoptotic phenotype would suggest that even in normal conditions, a small fraction of endogenous PrPc could be responsible for our observed p53-dependent caspase 3 activation.

We recently documented the fact that PrPc undergoes basal and protein kinase C-regulated cleavage in the middle of its 106-126 domain by proteases of the disintegrins family, thereby releasing a fragment that we called N1 (for review see Ref. 36). This PrPc cleavage also observed by Chen et al. (37) is reminiscent of the one taking place in the middle of the Abeta domain borne by the beta -amyloid precursor protein (38). Interestingly, this intra-Abeta cleavage not only lowers Abeta production but also gives rise to a cytotrophic and neuroprotective secreted fragment called sAPPalpha . Whether the cleavage generating N1 not only abolishes a pro-apoptotic control of PrP but also produces a fragment with opposite neuroprotective influence is currently being examined in our laboratory.

    ACKNOWLEDGEMENTS

We thank Prof. Weissmann (Imperial College, London, UK) for providing Prnp-/- mice. PG13-luciferase- and ASp53-cDNAs were generously provided by Dr. B. Vogelstein (Howard Hughes Medical Institute, Baltimore, MD). The p53-inactive NCI-H1299 cells were kindly provided by Drs. L. Mercken and L. Pradier (Aventis Pharma, Vitry sur Seine, France). We thank Drs. Y. Frobert and J. Grassi (Commissariat à l'Energie Atomique, Saclay, France) for the kind gift SAF32 monoclonals and Dr. P. Auberger (Nice, France) and M. P. Mattson (National Institute of Aging, Baltimore, MD) for the gift of PP2 and pifithrin-alpha inhibitors, respectively.

    FOOTNOTES

* This work was supported in part by the Groupe d'Intérél-Scientifique "Infections à prions" and by the CNRS and by INSERM.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Institut de Pharmacologie Moléculaire et Cellulaire, UMR6097 du CNRS, 660 route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France. Tel.: 33-4-93-95-77-60; Fax: 33-4-93-95-77-08; E-mail: checler@ipmc.cnrs.fr.

Published, JBC Papers in Press, January 14, 2003, DOI 10.1074/jbc.M211580200

    ABBREVIATIONS

The abbreviations used are: PrPc, cellular prion protein; MAPK, mitogen-activated protein kinase; AS, antisense; PI, propidium iodide; PP2, (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine); sts, staurosporine; XTT, sodium 3'-[1-(phenylamino)carbonyl-3,4-tetrazolium]-bis-(4-methoxy-6-nitro)benzene sulphonic acid hydrate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Prusiner, S. B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13363-13383[Abstract/Free Full Text]
2. Aguzzi, A., Montrasio, F., and Kaeser, P. S. (2001) Nat. Rev. Mol. Cell. Biol. 2, 118-126[CrossRef][Medline] [Order article via Infotrieve]
3. Ghetti, B., Piccardo, P., Frangione, B., Bugiani, O., Giaccone, G., Young, K., Prelli, F., Farlow, M. R., Dlouhy, S. R., and Tagliavni, F. (1996) Brain Pathol. 6, 127-145[Medline] [Order article via Infotrieve]
4. Büeler, H., Aguzzi, A., Sailer, A., Greiner, R., Autenried, P., Aguet, M., and Weissmann, C. (1993) Cell 73, 1339-1347[Medline] [Order article via Infotrieve]
5. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C., and Aguzzi, A. (1996) Nature 379, 339-343[CrossRef][Medline] [Order article via Infotrieve]
6. Telling, G. C., Parchi, P., DeArmond, S. J., Cortelli, P., Montagna, P., Gabizon, R., Mastrianni, J., Lugaresi, E., Gambetti, P., and Prusiner, S. B. (1996) Science 274, 2079-2082[Abstract/Free Full Text]
7. Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F., and Prusiner, S. (1998) Nat. Med. 4, 1157-1165[CrossRef][Medline] [Order article via Infotrieve]
8. Lawson, V. A., Priola, S. A., Wehrly, K., and Chesebro, B. (2001) J. Biol. Chem. 276, 35265-35271[Abstract/Free Full Text]
9. Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S., Prusiner, S. B., Aguet, M., and Weissmann, C. (1992) Nature 356, 577-582[CrossRef][Medline] [Order article via Infotrieve]
10. Mallucci, G. R., Ratté, S., Asante, E. A., Linehan, J., Gowland, I., Jefferys, J. G. R., and Collinge, J. (2002) EMBO J. 21, 202-210[Abstract/Free Full Text]
11. Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. (1994) Nature 369, 321-323[CrossRef][Medline] [Order article via Infotrieve]
12. Kurschner, C., and Morgan, J. I. (1995) Mol. Brain Res. 30, 165-168[Medline] [Order article via Infotrieve]
13. Bounhar, Y., Zhang, Y., Goodyer, C. G., and LeBlanc, A. (2001) J. Biol. Chem. 276, 39145-39149[Abstract/Free Full Text]
14. Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., and Tagliavini, F. (1993) Nature 362, 543-546[CrossRef][Medline] [Order article via Infotrieve]
15. Brown, D. R. (1999) J. Neurochem. 73, 1105-1113[CrossRef][Medline] [Order article via Infotrieve]
16. Jobling, M. F., Stewart, L. R., White, A. R., McLean, C., Friedhuber, A., Maher, F., Beyreuther, K., Masters, C. L., Barrow, C. J., Collins, S. J., and Cappai, R. (1999) J. Neurochem. 73, 1557-1565[CrossRef][Medline] [Order article via Infotrieve]
17. Westaway, D., DeArmond, S. J., Cayetano-Canlas, J., Groth, D., Foster, D., Yang, S.-L., Torchia, M., Carlson, G. A., and Prusiner, S. B. (1994) Cell 76, 117-129[Medline] [Order article via Infotrieve]
18. Vincent, B., Paitel, E., Frobert, Y., Lehmann, S., Grassi, J., and Checler, F. (2000) J. Biol. Chem. 275, 35612-35616[Abstract/Free Full Text]
19. Chun, J., and Jaenisch, R. (1996) Mol. Cell. Neurosci. 7, 304-321[CrossRef][Medline] [Order article via Infotrieve]
20. Bradford, M. M. (1976) Anal. Biochem. 72, 248-259[CrossRef][Medline] [Order article via Infotrieve]
21. Demart, S., Fournier, J. G., Cremignon, C., Frobert, Y., Lamoury, F., Marce, D., Lasmézas, C., Dormont, D., Grassi, J., and Deslys, J.-P. (1999) Biochem. Biophys. Res. Commun. 265, 652-657[CrossRef][Medline] [Order article via Infotrieve]
22. Alves da Costa, C., Ancolio, K., and Checler, F. (2000) J. Biol. Chem. 275, 24065-24069[Abstract/Free Full Text]
23. El-Deiry, W., Kern, S., Pietenpol, J., Kinzler, K., and Vogelstein, B. (1992) Nat. Gen. 1, 45-49[Medline] [Order article via Infotrieve]
24. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollock, B. A., and Connelly, P. A. (1996) J. Biol. Chem. 271, 695-701[Abstract/Free Full Text]
25. Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., and Gudkov, A. V. (1999) Science 285, 1733-1737[Abstract/Free Full Text]
26. Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone, D., D'Amico, D., Bodner, S., Oie, H. K., Linnoila, R. I., Mulshine, J. L., and Minna, J. D. (1992) Oncogene 7, 171-180[Medline] [Order article via Infotrieve]
27. Yin, Y., Luciani, M. G., and Fahraeus, R. (2002) Nat. Cell Biol.
28. Zhu, Y., Mao, X. O., Sun, Y., Xia, Z., and Greenberg, D. A. (2002) J. Biol. Chem. 277, 22909-22914[Abstract/Free Full Text]
29. Young, P. R., McLaughlin, M. M., Kumar, S., Kassis, S., Doyle, M. L., McNulty, D., Gallagher, T. F., Fisher, S., McDonnell, P. C., Carr, S. A., Huddleston, M. J., Seibel, G., Porter, T. G., Livi, G. P., Adams, J. L., and Lee, J. C. (1997) J. Biol. Chem. 272, 12116-12121[Abstract/Free Full Text]
30. Kuwahara, C., Takeuchi, A. M., Nishimura, T., Haraguchi, K., Kubosaki, A., Matsumoto, Y., Saeki, K., Matsumoto, Y., Yokoyama, T., Itohara, S., and Onodera, T. (1999) Nature 400, 225-226[CrossRef][Medline] [Order article via Infotrieve]
31. Schätzl, H. M., Laszlo, L., Holtzman, D. M., Tatzelt, J., DeArmond, S. J., Weiner, R. I., Mobley, W. C., and Prusiner, S. B. (1997) J. Virol. 71, 8821-8831[Abstract]
32. White, A. R., Guirguis, R., Brazier, M. W., Jobling, M. F., Hill, A. F., Beyreuther, K., Barrow, C. J., Masters, C. L., Colins, S. J., and Cappai, R. (2001) Neurobiol. Dis. 8, 299-316[CrossRef][Medline] [Order article via Infotrieve]
33. Paitel, E., Alves da Costa, C., Vilette, D., Grassi, J., and Checler, F. (2002) J. Neurochem. 83, 1208-1214[CrossRef][Medline] [Order article via Infotrieve]
34. Ma, J., Wollmann, R., and Lindquist, S. (2002) Science 298, 1781-1785[Abstract/Free Full Text]
35. Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J. L., Lehmann, S., Launay, J. M., and Kellermann, O. (2000) Science 289, 1925-1928[Abstract/Free Full Text]
36. Checler, F., and Vincent, B. (2002) Trends Neurosci. 25, 616-620[CrossRef][Medline] [Order article via Infotrieve]
37. Chen, S. G., Teplow, D. B., Parchi, P., Teller, J. K., Gambetti, P., and Autilio-Gambetti, L. (1995) J. Biol. Chem. 270, 19173-19180[Abstract/Free Full Text]
38. Checler, F. (1995) J. Neurochem. 65, 1431-1444[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.